Metoperan Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Side Effects Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Metoclopramide HCl

Indications/Uses

Symptomatic treatment of nausea & vomiting including migraine-induced nausea & vomiting in adults. Prevention of post-op & RT-induced nausea & vomiting in adults. 2nd-line option in prevention of post-op & delayed chemotherapy-induced nausea & vomiting in childn 1-18 yr.

Click to view Metoperan detailed prescribing information

Dosage/Direction for Use

IV/IM Adult 10 mg once-tds. Max daily dose: 30 mg or 0.5 mg/kg. Post-op nausea & vomiting 10 mg as single dose for 48 hr. Childn 15-18 yr, >60 kg 10 mg up to tds, 9-18 yr, 30-60 kg 5 mg up to tds, 5-9 yr, 20-29 kg 2.5 mg up to tds, 3-5 yr, 15-19 kg 2 mg up to tds, 1-3 yr, 10-14 kg 1 mg up to tds. Duration: 5 days. Max daily dose: 0.5 mg/kg. End-stage kidney failure (CrCl 15 mL/min) Reduce daily dose by 75%, moderate to severe kidney (CrCl 15-60 mL/min) & severe liver failure Reduce dose by 50%.

Click to view Metoperan detailed prescribing information

Overdosage

View Metoperan overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity. GI haemorrhage, mechanical obstruction or perforation; epilepsy; Parkinson's disease. Confirmed or suspected pheochromocytoma; history of neuroleptic- or metoclopramide-induced tardive dyskinesia; known history of methaemoglobinaemia w/ metoclopramide or of NADH cytochrome-b5 deficiency. Combination w/ l-dopa or dopaminergic agonists. Childn <1 yr.

Click to view Metoperan detailed prescribing information

Warnings

For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Metoperan detailed prescribing information

Special Precautions

Discontinue use if extrapyramidal symptoms, NMS, tardive dyskinesia, methaemoglobinemia occur. Patients w/ underlying neurological conditions, cardiac conduction disorders, electrolyte imbalance, bradycardia. May exacerbate symptoms of Parkinson's disease. High-dose & long-term treatment. Concomitant use w/ other centrally-acting drugs, drugs prolonging QT interval. Renal or severe hepatic impairment. Avoid use at the end of pregnancy. Not recommended during lactation. Not to be used in neonates. Avoid use in childn <2 yr. Elderly.

Click to view Metoperan detailed prescribing information

Use In Pregnancy & Lactation

Click to view Metoperan detailed prescribing information

Adverse Reactions

Somnolence. Diarrhoea; asthenia; extrapyramidal disorders, parkinsonism, akathisia; depression; hypotension.

Drug Interactions

Mutual antagonism w/ l-dopa or dopaminergic agonists. Potentiated sedative effect w/ alcohol, CNS depressants eg, morphine derivatives, anxiolytics, sedative H₁-antihistamines & antidepressants, barbiturates, clonidine. Antagonized GI motility w/ anticholinergics, morphine derivatives. Additive effect on extrapyramidal disorders occurrence w/ neuroleptics. Increased risk of serotonin syndrome w/ serotonergic drugs eg, SSRIs. Decreased digoxin bioavailability. Increased cyclosporine bioavailability. Prolonged neuromuscular block duration w/ mivacurium, suxamethonium. Increased exposure levels by CYP2D6 inhibitors eg, fluoxetine, paroxetine. Enhanced effects of paracetamol, aspirin. Reduced plasma conc of atovaquone. Concomitant use w/ MAOIs, sympathomimetics.

Click to view Metoperan detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Metoperan detailed prescribing information

Storage

View Metoperan storage conditions for details to ensure optimal shelf-life.

Description

View Metoperan description for details of the chemical structure and excipients (inactive components).

Action

View Metoperan mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antiemetics

ATC Classification

A03FA01 - metoclopramide ; Belongs to the class of propulsives. Used in the treatment of functional gastrointestinal disorders.

Regulatory Classification

Presentation/Packing

Form

Metoperan soln for inj 5 mg/mL

Packing/Price

2 mL x 10 × 1's

Metoperan

metoclopramide

Manufacturer:

Siu Guan

Distributor:

Averroes Pharma